Anti-thrombotic, anti-platelet and fibrinolytic therapy: current management of acute myocardial infarction
Date
2001
Authors
Helft, G.
Worthley, S.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Heart Lung and Circulation, 2001; 10(2):68-74
Statement of Responsibility
Gerard Helft and Stephen G. Worthley
Conference Name
Abstract
Significant advances in the treatment of patients with acute myocardial infarction (MI) have been obtained in recent times. In particular, thrombolytic therapy has been shown to preserve ventricular function and improve survival in patients with acute MI. Therapies now include third-generation thrombolytic agents, percutaneous transluminal coronary angioplasty (PTCA) and intracoronary stenting, and new anti-thrombotic therapies including anti-platelet treatment with glycoprotein (GP) IIb/IIIa inhibition and direct anti-thrombin agents. This review will focus on the use of GP IIb/IIIa antagonists and thrombin inhibitors as adjunctive therapies to thrombolytic treatment of patients with acute MI.
School/Discipline
Dissertation Note
Provenance
Description
The definitive version is available at www.blackwell-synergy.com